Abstract library

11 results for "Manoharan".
#746 Aspirin Delays the Development/Progression of Neuroendocrine Pancreatic Neoplasms and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Tumors
Introduction: So far, there are no chemopreventive strategies for neuroendocrine pancreatic neoplasms.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Others
Presenting Author: Prof.Dr. Volker Fendrich
#1002 Retrospective Study of MIBG Therapy for Phaeochromocytoma (PH) and Paraganglioma (PG): The Christie Experience
Introduction: PH & PG are rare neuroendocrine tumors treated with MIBG but protocols are not standardized and reported results are variable.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Dr Zena Salih
Keywords: mibg
#1098 177Lu Dotatate vs Sequential 177Lu Dotatate and 90Y Dotatate: Treatment Outcomes for PRRT Patients at the Christie - A Clinical Audit
Introduction: The traditional treatment regime of somatostatin receptor positive NETs by molecular radiotherapy was based on single radionuclides (e.g. 90Y Dotatate or 177Lu Dotatate), delivered as multiple cycles to allow normal tissue recovery. However a newer practice of alternating tcycles of 177Lu and Y90 Dotatate was implemented at the Christie following introduction of this regime in some European centres. Subsequent follow up studies have indicated that longer overall survival and reduced loss of kidney function is found in patient cohorts treated with combined 177Lu and 90Y regimes to either 177Lu or 90Y alone.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Emma Page
Authors: Page E, Tipping J, Birch E, Hamilton D, ...
Keywords: PRRT, Toxicity, Audit, RM Dose
#1306 The Role of Ga68-DOTATOC-PET-CT in Routine Screening of Multiple Endocrine Neoplasia Type 1
Introduction: Multiple endocrine neoplasia type 1 is a tumor syndrome characterized by NENs of the pancreas, duodenum, parathyroid, pituitary, adrenal, thymus and bronchi. Gene carriers are recommended participation in prospective screening programs at expert centers. Ga68-DOTATOC-PET-CT is an increasingly used very sensitive imaging technique for GEP-NENs.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Max Benjamin Albers
#1327 Is Screening of Young Asymptomatic MEN1 Patients Necessary?
Introduction: Recent clinical practice guidelines recommend that routine screening of MEN1 mutation carriers should start at the age of 5 years to detect MEN1-associated tumors which is controversial in the scientific community.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD Jerena Manoharan
Keywords: Screening, MEN1
#1438 An Unusual Phenotype of Multiple Endocrine Neoplasia Type 1 with a Small Intestine Neuroendocrine Tumor Associated with Large Deletion of the MEN1 Gene
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited tumor syndrome that is caused by germline mutations in the Menin suppressor gene on chromosome 11q13. Small intestine neuroendocrine neoplasias (SI-NEN) are currently not considered to be part of the phenotype of the MEN1-syndrome.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD Jerena Manoharan
#1486 Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1
Introduction: The role of minimally invasive pancreatic surgery for pancreatic neuroendocrine neoplasms (pNENs) in patients with multiple endocrine neoplasia type 1 (MEN1) is not well defined.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Caroline Lopez
#1518 Significance of Preoperative FDG-PET/CT Scan in Patients with Pulmonary Carcinoid Tumours
Introduction: FDG uptake on PET/CT scan has been shown to be of prognostic significance in patients (pts) with metastatic neuroendocrine tumours (NET).
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Georgios Papaxoinis
#1759 Safety and Tolerability of "Ready-to-Use" (SOMAKIT TOCĀ®) 68Ga-DOTA0-Tyr3-Octreotide (68Ga-DOTATOC) for Injection in Patients with Proven Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)
Introduction: 68Ga-DOTATOC (PET) has superior diagnostic performance than Octreoscan (SPECT) in patients with GEP-NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Angela Lamarca
Keywords: SomaKit, DOTATOC, GEP-NET
#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).
Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Jorge Barriuso
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.